Summit Therapeutics Inc vs Tapestry, Inc. — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Tapestry, Inc. trades at $154.3 (market cap $32.44B). The key difference: Tapestry, Inc. is far larger — about 2.7× Summit Therapeutics Inc's market cap, and Tapestry, Inc. pays a 1% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TPR | |
|---|---|---|
Market Cap | $12.06B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.98 | $164.78 |
52-Week Low | $12.55 | $95.69 |
Enterprise Value | $11.39B | $35.29B |
Dividend Yield | — | 1% |
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
TPR trades at $154.39, down 6.31% over 24 hours, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent earnings beats and a 75.61% buy rating highlight positive momentum. The company maintains robust gross margins of 76.18% and ROE of 55.74%, though elevated P/E of 48.95 signals premium valuation. Upcoming Q4 2026 earnings on August 13, 2026, and a $0.40 dividend payment on June 22, 2026, are key near-term catalysts.
Outlook remains favorable with a consensus price target of $190.33, implying 23% upside, driven by earnings growth and AI integration initiatives. Risks include high debt levels, competitive pressures, and sensitivity to consumer spending. Investors should weigh strong profitability against valuation concerns ahead of earnings.
Trailing returns across standard periods
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →